Related Experiment Video
Updated: Feb 24, 2026

A Treatment Package without Escape Extinction to Address Food Selectivity
Published on: August 21, 2015
Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic
Emma Medford1,2, Dougal Julian Hare3, Anja Wittkowski4,5
1School of Health Sciences, University of Manchester, Manchester, UK.
Insights
Phenylketonuria (PKU) management is challenging, as metabolic control worsens with age in children and adolescents. Interventions supporting treatment adherence are crucial for improving phenylalanine levels in this population.
Area of Science:
- Metabolic disorders
- Genetics
- Pediatric health
Background:
- Phenylketonuria (PKU) is a rare genetic disorder requiring lifelong dietary management to prevent cognitive impairment.
- Many children and adolescents with PKU struggle to maintain recommended blood phenylalanine levels.
- Understanding factors influencing metabolic control is vital for effective PKU management.
Purpose of the Study:
- To systematically review demographic and psychosocial factors associated with blood phenylalanine levels in children and adolescents with PKU.
- To identify robust predictors of metabolic control in pediatric PKU patients.
- To inform clinical practice and future research directions.
Main Methods:
- Systematic review of four electronic databases, yielding 1,808 articles.
- Inclusion criteria: statistical examination of demographic/psychosocial factors and blood phenylalanine concentration in pediatric PKU.
- Twenty-nine studies were selected for analysis.
Main Results:
- Metabolic control, measured by blood phenylalanine levels, was found to worsen with increasing child age.
- Several child, parent, and family factors were examined, but age showed the most reproducible association.
- A paucity of studies and variable study quality were noted.
Conclusions:
- Increasing age is a significant factor associated with poorer metabolic control in pediatric PKU.
- Adolescents with PKU may particularly benefit from interventions focused on treatment adherence.
- Further research is needed to strengthen the evidence base for clinical practice in PKU management.
Abstract:
Phenylketonuria (PKU) is a rare genetic disorder in which the amino acid phenylalanine cannot be sufficiently metabolised. Although a build-up of phenylalanine causes irreversible cognitive impairment, this can be prevented through a strict, lifelong diet restricted in natural protein. Despite the severe consequences of poor metabolic control, many children and adolescents have phenylalanine levels above their recommended limits. This systematic review was the first to examine studies reporting demographic and/or psychosocial influences on blood phenylalanine levels, with the aim to identify factors that were robustly linked with metabolic control. Four electronic databases were searched, yielding 1,808 articles. Articles were included if they reported a statistical examination of the association between one or more demographic or psychosocial factor(s) and metabolic control (as measured by blood phenylalanine concentration) for children and adolescents with PKU. Twenty-nine studies were selected for inclusion, which examined a range of child, parent and family factors related to blood phenylalanine levels. The most reproducible association was with child age, with metabolic control worsening with increasing age. This suggests that interventions promoting treatment adherence would be particularly beneficial for adolescents. There was a paucity of studies in some areas, and the quality of included studies varied; therefore, the conclusions of this review are preliminary. Research recommendations focus on promoting the growth of the evidence-base to support clinical practice.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
10:02Event Related Potentials ERPs and other EEG Based Methods for Extracting Biomarkers of Brain Dysfunction: Examples from Pediatric Attention Deficit/Hyperactivity Disorder ADHD
Published on: March 12, 2020
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacokinetics in Pediatric Patients: Drug Excretion
Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug Therapy
Antianxiety Medications
Chronic Kidney Disease III: Interprofessional Care